-
EP3802599
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3802599
| EP3802599 - BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 17.11.2023 Database last updated on 13.07.2024 | |
| Former | Grant of patent is intended Status updated on 03.07.2023 | ||
| Former | Examination is in progress Status updated on 06.05.2022 | ||
| Former | Request for examination was made Status updated on 12.03.2021 | ||
| Former | The international publication has been made Status updated on 14.12.2019 | ||
| Former | unknown Status updated on 14.06.2019 | Most recent event Tooltip | 12.07.2024 | Lapse of the patent in a contracting state New state(s): SM | published on 14.08.2024 [2024/33] | Applicant(s) | For all designated states LamKap Bio beta AG Bahnhofstrasse 1 8808 Pfaeffikon Schwyz / CH | [2023/51] |
| Former [2021/15] | For all designated states LamKap Bio beta AG Bahnhofstrasse 1 8808 Pfaeffikon Schwyz / CH | Inventor(s) | 01 /
BUATOIS, Vanessa 32D chemin de la Clunaz 74270 Contamine-Sarzin / FR | 02 /
MAJOCCHI, Sara Chemin de Sous-Bois 3 1212 Grand Lancy / CH | 03 /
STREIN, Klaus Panoramastrasse 14 69469 Weinheim / DE | [2021/15] | Representative(s) | Bassil, Nicholas Charles, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [2023/51] |
| Former [2021/15] | Schreiner, Siegfried Finkenweg 1 82362 Weilheim / DE | Application number, filing date | 19728547.1 | 31.05.2019 | [2021/15] | WO2019IB54559 | Priority number, date | EP20180175655 | 03.06.2018 Original published format: EP 18175655 | EP20180175656 | 03.06.2018 Original published format: EP 18175656 | EP20180175657 | 03.06.2018 Original published format: EP 18175657 | EP20180175658 | 03.06.2018 Original published format: EP 18175658 | EP20180188788 | 13.08.2018 Original published format: EP 18188788 | EP20180188790 | 13.08.2018 Original published format: EP 18188790 | EP20180188792 | 13.08.2018 Original published format: EP 18188792 | EP20180190983 | 27.08.2018 Original published format: EP 18190983 | [2021/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019234576 | Date: | 12.12.2019 | Language: | EN | [2019/50] | Type: | A1 Application with search report | No.: | EP3802599 | Date: | 14.04.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 12.12.2019 takes the place of the publication of the European patent application. | [2021/15] | Type: | B1 Patent specification | No.: | EP3802599 | Date: | 20.12.2023 | Language: | EN | [2023/51] | Search report(s) | International search report - published on: | EP | 12.12.2019 | Classification | IPC: | C07K16/28, C07K16/30, A61K39/395, A61P35/00 | [2021/15] | CPC: |
C07K16/3007 (EP,KR,US);
C07K16/2803 (EP,KR,US);
A61P35/00 (EP,KR);
C07K16/2809 (EP,KR,US);
C12N15/85 (US);
A61K2039/505 (EP,US);
C07K2317/31 (EP,KR,US);
C07K2317/41 (EP,KR,US);
C07K2317/52 (US);
C07K2317/565 (KR,US);
C07K2317/622 (EP,KR,US);
C07K2317/73 (EP);
C07K2317/732 (EP,KR,US);
C07K2317/76 (EP,KR,US);
C07K2317/92 (EP,KR,US);
C12N2015/8518 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/15]
| Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | BISPEZIFISCHE ANTIKÖRPER GEGEN CEACAM5 UND CD47 | [2021/15] | English: | BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | [2021/15] | French: | ANTICORPS BISPÉCIFIQUES DIRIGÉS CONTRE CEACAM5 ET CD47 | [2021/15] | Entry into regional phase | 11.01.2021 | National basic fee paid | 11.01.2021 | Designation fee(s) paid | 11.01.2021 | Examination fee paid | Examination procedure | 01.12.2020 | Amendment by applicant (claims and/or description) | 11.01.2021 | Examination requested [2021/15] | 11.01.2021 | Date on which the examining division has become responsible | 10.05.2022 | Despatch of a communication from the examining division (Time limit: M04) | 05.07.2022 | Reply to a communication from the examining division | 18.08.2022 | Despatch of a communication from the examining division (Time limit: M04) | 21.10.2022 | Reply to a communication from the examining division | 23.12.2022 | Despatch of a communication from the examining division (Time limit: M04) | 13.04.2023 | Reply to a communication from the examining division | 04.07.2023 | Communication of intention to grant the patent | 13.11.2023 | Fee for grant paid | 13.11.2023 | Fee for publishing/printing paid | 13.11.2023 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 31.05.2021 | Renewal fee patent year 03 | 31.05.2022 | Renewal fee patent year 04 | 31.05.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HR | 20.12.2023 | RS | 20.12.2023 | SM | 20.12.2023 | NO | 20.03.2024 | GR | 21.03.2024 | IS | 20.04.2024 | [2024/33] |
| Former [2024/32] | HR | 20.12.2023 | |
| RS | 20.12.2023 | ||
| NO | 20.03.2024 | ||
| GR | 21.03.2024 | ||
| IS | 20.04.2024 | ||
| Former [2024/25] | HR | 20.12.2023 | |
| RS | 20.12.2023 | ||
| NO | 20.03.2024 | ||
| GR | 21.03.2024 | ||
| Former [2024/20] | GR | 21.03.2024 | Cited in | International search | [A]WO2012023053 (NOVIMMUNE SA [CH], et al); | [A]WO2014056783 (ROCHE GLYCART AG [CH]); | [I]WO2014087248 (NOVIMMUNE SA [CH]); | [A]WO2017027422 (ALEXO THERAPEUTICS INC [US]); | [A]WO2017118675 (HOFFMANN LA ROCHE [CH], et al); | [A]WO2017121771 (BLINK BIOMEDICAL SAS [FR]); | [XI]WO2018098384 (UNIV CALIFORNIA [US]); | by applicant | WO9954342 | WO0041474 | EP1176195 | US2002165360 | US2003115614 | WO03056914 | US6602684 | US2003157108 | US2003175884 | WO03084570 | WO03085119 | WO03099196 | WO2004024927 | US2004093621 | US2004110282 | US2004110704 | US2004132140 | WO2004057002 | WO2004063351 | WO2004065540 | WO2004099249 | US2004241817 | WO2005018669 | WO2005018572 | WO2005056759 | US2005147614 | WO2005063815 | US6946292 | WO2005092925 | WO2005110474 | WO2006019447 | WO2006023420 | WO2006047350 | WO2006085967 | WO2006105338 | WO2006116260 | WO2007005874 | WO2007008943 | WO2007021841 | WO2007024249 | WO2007041635 | WO2007042261 | WO2007044616 | WO2007048077 | WO2007071426 | WO2007106707 | WO2008015671 | WO2008022152 | WO2008036688 | WO2008091798 | WO2008091954 | WO2008092117 | WO2008098115 | US7425446 | WO2008119565 | WO2008119566 | WO2008119567 | WO2008121160 | WO2008140603 | WO2008150494 | WO2008156712 | US7521051 | WO2009101611 | WO2009114335 | WO2010027423 | WO2010027827 | WO2010027828 | WO2010033736 | WO2010037836 | WO2010037837 | WO2010037838 | WO2010077634 | EP2282773 | US2011064653 | US8008449 | US8067232 | WO2012023053 | US2012184716 | US8236308 | WO2012117002 | US2012251529 | US8354509 | WO2013012414 | WO2013019906 | US8383796 | WO2013088259 | WO2013173223 | EP2681244 | US2014140989 | WO2014087248 | WO2014113510 | US2014242079 | US2014303354 | WO2015026634 | WO2015112534 | WO2016007235 | WO2016036678 | US2016144009 | WO2016116907 | WO2016156537 | US2016333093 | WO2017005389 | WO2017055389 | WO2017118657 | WO2017118675 | EP3199552 | WO2017196793 |